The aim of this study was to investigate inequalities in survival for non-Hodgkin's lymphoma (NHL), distinguishing between direct and indirect effects of patient, social and process-ofcare factors. All cases of NHL diagnosed in Ireland in 2004-2008 were included. Variables describing patient, cancer, stage and process of care were included in a discrete-time model of survival using Structural Equation Modelling software. Emergency admissions were more common in patients with co-morbid conditions or with more aggressive cancers, and less frequent for patients from more affluent areas. Aggressive morphology, female sex, emergency admission, increasing age, comorbidity, treatment in a high caseload hospital and late stage were associated with ...
Background: The association between socioeconomic status (SES) and cancer survival has been studied ...
Due to the addition of innovative treatment, survival of non-Hodgkin lymphoma (NHL) increased during...
The influence of socioeconomic status (SES) on access to standard chemotherapy and/or monoclonal ant...
The aim of this study was to investigate inequalities in survival for non-Hodgkin's lymphoma (NHL), ...
The aim of this study was to investigate inequalities in survival for non-Hodgkin's lymphoma (NHL), ...
BACKGROUND: Not all patients have benefited equally from the advances in non-Hodgkin lymphoma (NHL) ...
IF 7.702International audienceThe survival of patients with diffuse large B-cell lymphoma has increa...
La survie des lymphomes non hodgkiniens (LNH) en population générale s'est améliorée durant la derni...
BackgroundPrevious studies documented racial/ethnic and socioeconomic disparities in survival after ...
Introduction: In patients with diffuse large B-cell lymphoma (DLBCL) socioeconomic status (SES) is a...
Shorter survival has been associated with low socioeconomic status (SES) among elderly non-Hodgkin's...
Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. N...
Abstract Background: Survival from Hodgkin’s lymphoma (HL) increased during the last ...
(1) Background: Socioeconomic inequalities of survival in patients with lymphoma persist, which may ...
PurposeHodgkin lymphoma (HL) survivors experience high risks of second cancers and cardiovascular di...
Background: The association between socioeconomic status (SES) and cancer survival has been studied ...
Due to the addition of innovative treatment, survival of non-Hodgkin lymphoma (NHL) increased during...
The influence of socioeconomic status (SES) on access to standard chemotherapy and/or monoclonal ant...
The aim of this study was to investigate inequalities in survival for non-Hodgkin's lymphoma (NHL), ...
The aim of this study was to investigate inequalities in survival for non-Hodgkin's lymphoma (NHL), ...
BACKGROUND: Not all patients have benefited equally from the advances in non-Hodgkin lymphoma (NHL) ...
IF 7.702International audienceThe survival of patients with diffuse large B-cell lymphoma has increa...
La survie des lymphomes non hodgkiniens (LNH) en population générale s'est améliorée durant la derni...
BackgroundPrevious studies documented racial/ethnic and socioeconomic disparities in survival after ...
Introduction: In patients with diffuse large B-cell lymphoma (DLBCL) socioeconomic status (SES) is a...
Shorter survival has been associated with low socioeconomic status (SES) among elderly non-Hodgkin's...
Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. N...
Abstract Background: Survival from Hodgkin’s lymphoma (HL) increased during the last ...
(1) Background: Socioeconomic inequalities of survival in patients with lymphoma persist, which may ...
PurposeHodgkin lymphoma (HL) survivors experience high risks of second cancers and cardiovascular di...
Background: The association between socioeconomic status (SES) and cancer survival has been studied ...
Due to the addition of innovative treatment, survival of non-Hodgkin lymphoma (NHL) increased during...
The influence of socioeconomic status (SES) on access to standard chemotherapy and/or monoclonal ant...